Superworth

Kymera Therapeutics free cash flow KYMR

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$238M
Latest quarter, Q2 FY26
−$54.5M
Fiscal year 2025
−$234.3M

Kymera Therapeutics' free cash flow was −$238M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$54.5M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$234.3Mn/a
FY2024−$207.3Mn/a
FY2023−$137.3Mn/a
FY2022−$155.9Mn/a
FY2021−$130.5M−265%
FY2020$79Mn/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$54.5Mn/a−$238M
Q1 FY26−$89.3Mn/a−$244M
Q4 FY25−$66.9Mn/a−$234.3M
Q3 FY25−$27.3Mn/a−$230.2M
Q2 FY25−$60.6Mn/a−$252.9M
Q1 FY25−$79.6Mn/a−$240M
Q4 FY24−$62.7Mn/a−$207.3M
Q3 FY24−$50Mn/a−$148.2M
Q2 FY24−$47.6Mn/a−$137.9M
Q1 FY24−$47Mn/a−$136.3M
Q4 FY23−$3.6Mn/a−$137.3M
Q3 FY23−$39.7Mn/a−$173.6M

Against its peers

Companies in Biotechnology nearest Kymera Therapeutics' size, closest first, today.

CompanyFree cash flow yield
KYMRKymera Therapeutics−2.6%
KRYSKrystal Biotech2.8%
RGENRepligen1.1%
TECHBIO-TECHNE2.3%
HALOHalozyme Therapeutics5.7%
NBIXNeurocrine Biosciences6.0%
EXELExelixis7.3%
INCYIncyte8.2%
UTHRUnited Therapeutics4.3%
ALNYAlnylam Pharmaceuticals2.6%
ADMAAdma Biologics4.9%
Peer median4.6%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Kymera Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.